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Immunity conferred by antigen-specific CD4+T cells is critical for controlling infection with
Mycobacterium tuberculosis (Mtb), the causative agent of tuberculosis. However, despite
research that spans more than a century, many of the characteristics of protective immune
responses to Mtb remain elusive. Defining the repertoire of antigenic targets is central to
understanding the immune response against this pathogen. Although traditional methods
of antigen discovery have identified many immunodominant antigens, they afford limited
proteome coverage. Recent advances in proteomic techniques that are based on peptide
library and protein microarray technology have enabled interrogation of the entire proteome
of Mtb for antigens. Though these techniques have limitations and are still evolving, early
studies using these techniques provide an unbiased view of the immune response to Mtb.
Here we review proteome-wide approaches to antigen discovery and summarize what
these have revealed so far on the composition of the Mtb immunoproteome.
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INTRODUCTION
Decades of research on T cell responses to Mycobacterium tuber-
culosis (Mtb) have identified many immunodominant antigens,
some of which provide significant protection as immunogens in
animal models (1). A major focus has been to identify antigens
recognized by CD4+ T cells, since these cells are believed to play a
dominant role in controlling Mtb infection (2). However, robust
immune responses induced by immunodominant antigens do not
necessarily translate into protective immunity (3), which reflects
the complex and incompletely understood role of host immunity
in the natural history of tuberculosis. On the one hand, antigen-
specific CD4+ T cell responses are critical for protection against
tuberculosis, and Mtb has evolved many strategies that subvert and
evade the host adaptive immune response (4). On the other hand,
Mtb exploits immune responses for its own benefit, and evidence
suggests that immune-mediated tissue destruction facilitates the
spread of Mtb among hosts. In agreement with this, recent studies
have found that T cell epitopes of known immunodominant anti-
gens of Mtb are hyperconserved, implying that immune responses
against them may be in some cases more beneficial to the bacilli
than to the host (5).
Given this complex relationship between host and pathogen, a
full definition of the antigenic repertoire or“immunoproteome”of
Mtb is an important step toward understanding how to effectively
vaccinate against this infection. Until recently, most approaches
to antigen discovery were based on traditional methods for sepa-
ration and identification of antigens from complex mycobacterial
protein mixtures (6). Alternative methods have employed screen-
ing of Mtb expression libraries in Escherichia coli with T cell clones
derived from latently infected individuals (7). Although these
methods have been successful in identifying immunodominant
antigens, they provide restricted coverage of the Mtb proteome
which has over 4,000 proteins. Advances in proteome-wide screen-
ing methods now enable a more extensive and unbiased survey of
antigenic targets on complex pathogens like Mtb. Here, we review
results from recently published proteome-wide antigen screens,
and discuss how this powerful new approach may improve our
understanding of the CD4+ T cell response to Mtb.
DEFINING THE IMMUNOPROTEOME OF Mtb
With the development of technologies that allow high-throughput
peptide and protein synthesis, it is now possible to interrogate the
entire Mtb proteome for antigens. So far, three proteome-wide
and relatively unbiased approaches to identify candidate antigens
for CD4+ T cell responses from the Mtb proteome have been
described (Figure 1). One approach was based on the use of a
peptide library designed to screen potential targets of CD4+ T
cell responses in latently infected individuals (8). In contrast to
previous studies which typically involved in vitro expansion of
Mtb-specific T cells, circulating T cells from Mtb infected donors
were directly tested against the synthetic peptide library using
IFNγ ELISPOT assay. This screen involved predicting Mtb pep-
tides that bind with high affinity to commonly expressed MHC
class II alleles using a consensus approach based on results from
three prediction methods (9). Two other studies used analysis
of serum antibody responses as a surrogate for CD4+ T cell
responses, relying on the assumption that a strong linkage exists
between the targets of antibodies and of the CD4+ helper T cells
involved in their generation (10). In one case, protein microar-
rays printed with products of all expressed open reading frames
of Mtb were used to screen sera from TB patients and controls
for antibody reactivity (11). In the other study, a similar screen for
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FIGURE 1 | Summary of proteome-wide screens for Mtb antigens.
(A) Summary of screen for targets of CD4+T cells (8). Mtb peptide
sequences that represented 5 complete and 16 incomplete Mtb genomes
were analyzed by HLA Class II consensus prediction method for binding to
22 of the most commonly expressed alleles of HLA-DR, -DP, and -DQ
sequences. Peptides predicted to bind with high affinity were synthesized
and tested by ELISPOT for stimulation of IFNγ production by circulating T
cells of 28 latently infected, non-BCG vaccinated donors from a
non-endemic area. Among the 369 reactive peptides, 80 peptides
accounted for 75% of the total response. (B) Summary of one of two
published screens for targets of humoral responses (11). Approximately
95% of the open reading frames of Mtb (H37Rv strain) corresponding to
3,988 proteins were cloned and expressed in vitro in an Escherichia
coli -based cell-free transcription/translation system. The crude reactions
containing expressed proteins were printed directly onto
nitrocellulose-coated slides without purification. These slides were then
probed with sera from uninfected healthy individuals from a non-endemic
country (n=64) and suspected cases of TB (TB and non-TB pulmonary
patients) from endemic countries (n=561). The proteins that reacted to
sera from endemic countries but not to sera of uninfected individuals were
defined as antigens associated with infection. Among 484 such antigens,
198 reacted to more than one serum from endemic countries and were
designated frequent reactors. Proteins associated with disease were
identified by comparing responses in TB patients and non-TB patients.
serum antibody responses against the Mtb proteome in TB patients
was performed using traditional methods of recombinant protein
expression and ELISA (12).
Despite major differences in their goals and methodology, all
studies concluded that human immune responses target a sub-
set of the Mtb proteome during infection (Figure 1). In the direct
screen for CD4+T cell responses to synthetic peptides,∼2% of the
proteome accounted for 80% of the total responses (8). With the
serum antibody-based screens, a larger fraction of the proteome
was found to be immunogenic, constituting ∼6–10% of the pro-
teome (11,12). In part, this difference may reflect that the latter two
studies screened for immune responses in active TB patients, who
would generally be expected to have higher bacterial burdens than
the latently infected individuals studied by Lindestam Arlehamn
et al. A striking feature of all studies was that the subset of the
proteome that induced an immune response (i.e., the immunopro-
teome) was enriched for secreted and cell wall-associated proteins.
This is consistent with earlier studies which have suggested that the
immunodominant antigens of mycobacteria are proteins that are
secreted by the bacteria during infection, and also with the recent
finding that mycobacteria secrete membrane vesicles rich in anti-
gens (13). Although the components of the immunoproteome
varied and showed only partial overlap among these studies, a
consistent finding was the remarkable prominence of immune
responses directed at members of the PE/PPE and ESX protein
families, which are well known as critical virulence determinants
of mycobacteria.
PE/PPE PROTEINS AS TARGETS OF CD4+ T CELLS
PE/PPE proteins are unique proteins found exclusively in path-
ogenic mycobacteria. There are genes for 99 PE proteins and
68 PPE proteins in the genome of Mtb, constituting ∼10% of
its coding capacity (14). They are characterized by the presence
of proline-glutamic acid (PE) and proline-proline-glutamic acid
(PPE) motifs near their N-termini (15). These proteins are further
divided into subfamilies based on the motifs in their C-termini
(Figure 2). Many PE/PPE proteins are localized to the bacterial
cell surface and many are secreted, making them readily accessible
to the immune system (16). Indeed, PE/PPE proteins are known
to induce strong humoral and cellular immune responses based
on studies that used traditional immunological assays (17). In the
genome, PE/PPE genes are often found within operons or gene
clusters that also contain a variety of other types of genes. Most
notably, genes for some PE/PPE proteins map within gene clusters
encoding type VII secretion systems, which are known as ESX sys-
tems in mycobacteria (see below). Secretion of some of the PE/PPE
proteins is known to be dependent on ESX systems, and compar-
ative genomics studies suggest that ESX clusters have coevolved
with PE/PPE proteins. The role of this distinct family of proteins
in mycobacterial virulence is yet to be determined, although stud-
ies suggest involvement in many aspects of pathogenesis including
bacterial attachment to host cells, immunomodulation, and ability
to persist in granulomas (15, 17).
All three published proteome-wide antigen screens showed that
PE/PPE proteins are major targets of human immune responses.
Among the antigens identified by peptide library screening for
CD4+ T cell responses, ∼45% were PE/PPE proteins though
they constitute <5% of the open reading frames of Mtb. In
addition, PE/PPE proteins represented approximately half of the
novel antigens identified, suggesting that immune responses to
these proteins remain mostly unexplored. Proteome-wide anti-
body screening also revealed an enrichment of PE/PPE proteins
among the antigens though the enrichment was less than that
observed for CD4 responses (an average of ∼5–6% of the total
targets recognized). It is possible that the relatively lower enrich-
ment found for these proteins for antibody responses compared
to cellular responses could in part reflect difficulties in expressing
these proteins by recombinant techniques that were used to gener-
ate antigens for the antibody-based screening. The identification
of PE/PPE proteins as prominent antigenic targets of CD4+ T
cells in these studies of the immunoproteome is consistent with
other more targeted analyses showing that these proteins are highly
immunogenic in mycobacteria-infected humans and cattle (18).
COMPONENTS OF ESX SECRETION SYSTEM AS TARGETS OF
CD4+ T CELLS
ESX secretion systems are specialized protein export systems orig-
inally identified in mycobacteria and constitute a distinct mecha-
nism for protein secretion known as the type VII secretion system.
Frontiers in Immunology | Antigen Presenting Cell Biology October 2013 | Volume 4 | Article 335 | 2
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Kunnath-Velayudhan and Porcelli The immunoproteome of Mycobacterium tuberculosis
FIGURE 2 | PE/PPE and ESX proteins. (A) Classification of PE/PPE
proteins. PE/PPE proteins are broadly divided into PE and PPE proteins
based on their characteristic N-terminal proline-glutamic acid (PE) and
proline-proline-glutamic acid (PPE) sequences. These motifs occur within a
span of ∼110 aminoacids in PE proteins and ∼180 aminoacids in PPE
proteins. The PE family is further subdivided into two groups based on the
presence or absence of a C-terminal domain with multiple tandem repeats
of Gly-Gly-Ala or Gly-Gly -Asn sequences (PGRS, polymorphic GC-rich
repetitive sequences). The PPE family is subdivided into three groups based
on characteristic motifs in their C-termini, as indicated. (B) General features
of ESX secretion systems. Organization of genes in the ESX-3 cluster, which
induced maximal responses in the CD4+T cell screen, are shown along
with a schematic of a typical ESX or type VII secretion system. All ESX
clusters contain a pair of Esx genes, the products of which form 1:1
complexes that are secreted. ESX clusters can exist as either complete
(designated ESX-1 through ESX-5 systems) or partial clusters. In addition to
the two Esx genes, complete ESX clusters encode four core components
(ESX core component, Ecc) which are EccA (an ATPase), EccB (a membrane
protein), EccC (an ATPase), EccD (a transmembrane protein), EccE (a
transmembrane protein), and EccF (MycP, a subtilisin-like serine protease).
Based on the current model of type VII secretion system, Esx heterodimers
are recognized by EccC which then form an active ATPase providing energy
for transport. EccC then propels these substrates through EccD, the
transmembrane protein forming the export channel. MycP might be involved
in processing certain substrates. The channel that transports the substrates
thought the mycolate layer is yet to be identified. ESX clusters contain
additional genes that code for other proteins called ESX
secretion-associated proteins (Esp). In most of the complete and
incomplete ESX systems, a pair of genes that code for PE/PPE proteins also
exists in close proximity to the Esx genes.
The system is named after two proteins, EsxA (also known as Early
Secretory Antigenic Target-6, or ESAT-6) and EsxB (Culture Fil-
trate Protein-10, or CFP-10). There are five complete (ESX-1–5)
and five to six incomplete ESX secretion systems in Mtb, and all
carry a pair of genes that encode homologs of EsxA and EsxB
(Figure 2). Most of the complete and incomplete ESX systems
also contain or are closely linked to a pair of genes that code for
PE/PPE proteins. These secretion systems export small proteins
that contain a WXG amino acid motif (tryptophan and glycine
separated by one amino acid). Secretion of EsxA and EsxB or
their homologs, as well as many PE/PPE proteins, is dependent
on ESX systems. Despite similarities, ESX systems do not com-
plement each other and each one is likely to play distinct roles in
Mtb virulence and physiology. For example, ESX-1 is required for
survival of mycobacteria in mice, for granuloma formation, and
for escape of Mtb from phagosome into cytosol (19, 20). Simi-
larly, ESX-3 is involved in iron and zinc uptake by the bacteria,
while ESX-5 has a role in modulating immune responses (20). It
should be noted that these systems and their homologs are found in
pathogenic and non-pathogenic mycobacteria and in other gram
positive bacteria (21).
ESX proteins are among the well known immunodominant
antigens of Mtb. Commercial tests for Mtb infection (QuantiF-
ERON® and T-SPOT.TB) use EsxA and EsxB as antigens since
circulating T cells from most infected individuals respond strongly
to these proteins. However, the proteome-wide screens reveal for
the first time the extent of immunodominance of ESX proteins.
For example, Lindestam Arlehamn et al. showed that 42% of the
cellular responses they detected were directed against a set of pro-
teins that represented 0.55% of the Mtb genome. These proteins
were encoded by genes located in three distinct regions of the
Mtb genome, which the authors called antigenic islands. All three
islands include Esx protein pairs (i.e., EsxA/EsxB or homologs) and
two contain the complete type VII secretion systems ESX-1 and
ESX-3. Immunoproteome analysis using antibody screening also
revealed that components of ESX systems induce strong immune
responses in humans. Pathway analysis of the data from probing
of microarrays with sera from active TB patients showed a sig-
nificant enrichment in reactivity to proteins controlled by Zur, a
regulator of Zinc uptake. Zur regulates a set of 56 genes which
includes genes that code for three ESX systems. Interestingly, two
of these three systems (ESX-3 and a partial ESX cluster containing
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genes for EsxQ, EsxR, and EsxS) were included in the three anti-
genic islands identified in the proteome-wide screen for CD4+
T cell responses. In addition, two proteins of the ESX-1 system
were among the top five antigens associated with active TB. Col-
lectively, these data underscore the immunodominance of ESX
systems.
Surprisingly, it appears that both secreted and non-secreted
components of the ESX systems induce strong immune responses.
For example, previous studies have shown that eight different
T cell antigens are encoded by genes in and around the ESX-
1 region. Since the antigens tend to cluster in the genome, ESX
systems had been called immunogenicity islands (22). It is not
clear how the non-secreted components of the ESX secretion
systems induce strong immune responses compared to other unre-
lated, surface-associated proteins. Since homologs of ESX systems
exist in many bacteria, it is possible that cross-reactive epitopes
may contribute to enhanced recognition of non-secreted com-
ponents. Co-regulation might also explain some of the immun-
odominance. For example, bacteria may overexpress secreted and
non-secreted components of the ESX-3 system in conditions of
low iron or zinc. In addition, the components of these systems
might exist as multi-protein aggregates, as shown for the ESX-5
system (23). This could favor the spreading of immune responses
from epitopes of the secreted components to epitopes of the non-
secreted components. Another possibility is that the secretion
system may form structures protruding from the bacterial cell
surface, thus increasing accessibility to antigen processing machin-
ery (19). Although the immunoproteome analysis suggested that
ESX proteins, and less strikingly PE/PPE proteins, in the anti-
genic islands were more immunogenic than their counterparts
encoded in other areas of the genome (8), other more focused
studies in M. bovis infected cattle have not confirmed this finding
(18, 22, 24).
LIMITATIONS OF CURRENT METHODS FOR PROTEOME-WIDE
SCREENING
Although uniquely powerful, high-throughput approaches of anti-
gen discovery do not necessarily capture responses to all immun-
odominant antigens. For example, in the screen for cellular
responses, only 20–25% of the latently infected donors responded
to EsxA or EsxB (8). These antigens are known to induce responses
in most latently infected individuals, which is the basis for their
use in commercial ex vivo tests for latent infection. Similarly,
in another analysis of 18 latently infected individuals based on
responses to peptide libraries (25), no responses were detected to
the TB7.7 antigen. This antigen is also used in a commercial test
for latent infection and stimulates responses in approximately half
of infected individuals (26, 27). Similarly, proteome-wide screens
based on expression of recombinant proteins may yield false neg-
ative results because of failure to express certain Mtb proteins.
Indeed, the microarray-based screen for humoral responses failed
to detect some known immunodominant antigens, importantly
EsxA (11). In addition, the screen by Li et al. failed to detect
responses to both EsxA and EsxB. Another limitation is that pre-
selection of peptides that are predicted to bind to MHC class
II molecules by Lindestam Arlehamn et al. may have excluded
some immunodominant peptides, since the performance of the
predictive algorithms used is known to suffer from a significant
rate of both false positive and false negative errors (9).
CONSERVATION VERSUS VARIATION OF EPITOPE
SEQUENCES
The question of whether certain immune responses induced by
Mtb antigens could actually be more beneficial to the bacteria than
to the host remains open. According to classical models that por-
tray the host-pathogen interaction as an “evolutionary arms race,”
immunodominant epitopes are likely to be less conserved due to
high selection pressure from the immune response. Recent studies
suggest that this model may not consistently apply to mycobacte-
ria. By analyzing genome sequences of a diverse collection of Mtb
strains, Comas et al. showed that the great majority of known T
cell epitopes display little sequence variation, with lower ratios of
non-synonymous to synonymous changes than seen in other cod-
ing regions of essential and non-essential genes (5). Though the
study by Comas et al. excluded members of PE/PPE protein family
for technical reasons, a recent study of Mtb isolates showed that
PE/PPE proteins are also not under diversifying selection pressure
(28). One caveat of these studies is that they used epitope sequences
that were originally identified from studies that used the genomic
sequence of a single laboratory strain of Mtb (H37Rv), and this
approach would be expected not to include epitopes that are highly
variable among random clinical isolates. Thus, the analysis may
have been inadvertently restricted to invariant epitopes, leading
to severe biasing of the results. In addition, use of a small num-
ber of antigens might have caused further bias, as approximately
two thirds of the epitopes in the database used to design these
studies (the Immune Epitope Database) are derived from only
thirty antigens (29). In contrast to the studies showing conserva-
tion of epitope sequences, another study has shown evidence for
sequence variation in known T cell epitopes suggesting that they
may diversify in order to evade immune recognition (30). Thus,
a clear and consistent picture of the level of epitope conservation
versus variation has yet to be established.
For antigens that derive from multigene families such as the
PE/PPE and ESX proteins, another potentially important feature
that may contribute to immunodominance is the presence of
cross-reactive epitopes that are shared by multiple homologous
family members. Indeed, PE/PPE proteins are known to carry
highly conserved sequences. The relevance of this point was sug-
gested by a study showing that both magnitude and frequency
of T cell responses to PE/PPE proteins were greater to peptide
pools representing the more conserved N-terminal regions than
to pools representing other regions of the proteins (18). In addi-
tion, a majority of the reactive peptides showed more than 70%
sequence similarity to one or more additional PE/PPE regions,
further suggesting that cross reactivity contributes significantly
to responses to PE/PPE proteins. Another study which examined
responses to ESX-5 encoded PE/PPE proteins in mice also con-
cluded that cross-reactive epitopes contribute significantly to the
immunodominance of PE/PPE proteins (31). However, in contrast
to the response to PE/PPE proteins, analysis of bovine responses to
ESX proteins did not reveal an association between immunodom-
inance of specific epitopes and their level of cross reactivity with
other homologous Esx proteins (24).
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CONCLUSION
New methods enabling proteome-wide antigen screens provide
for the first time a general view of the immune responses induced
by Mtb. The data obtained so far using these methods indi-
cate that during Mtb infection, immune responses target a small
subset of the proteome enriched for membrane-associated and
secreted proteins. Among these antigens, members of the fam-
ilies of PE/PPE and ESX proteins are major targets of immune
responses. These results should encourage future efforts to char-
acterize the role of these protein families in pathogenesis, and
stimulate interest in developing them as components of novel
vaccines. While these two protein families comprise important
potential components of novel vaccines, it remains to be deter-
mined whether the most prominent antigens in natural infec-
tion are also among the most effective antigens in the context
of vaccination. Since most of the data obtained so far have
come from analyses of immune responses in chronically infected
individuals, it will be important to extend these studies to sub-
jects with acute infection who may target a different antigenic
repertoire.
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